These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9514453)

  • 1. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    Schwartz GG; Oliver MF; Ezekowitz MD; Ganz P; Waters D; Kane JP; Texter M; Pressler ML; Black D; Chaitman BR; Olsson AG
    Am J Cardiol; 1998 Mar; 81(5):578-81. PubMed ID: 9514453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
    JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
    Waters DD; Schwartz GG; Olsson AG; Zeiher A; Oliver MF; Ganz P; Ezekowitz M; Chaitman BR; Leslie SJ; Stern T;
    Circulation; 2002 Sep; 106(13):1690-5. PubMed ID: 12270864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the Myocardial Ischemia Reduction With Aggressive Cholesterol lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    Ghali JK
    Am J Cardiol; 1998 Sep; 82(5):703. PubMed ID: 9732912
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA; Casciano R; Stern L; Rejas J
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.
    Buller N; Gillen D; Casciano R; Doyle J; Wilson K
    Pharmacoeconomics; 2003; 21 Suppl 1():25-32. PubMed ID: 12648032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Meeting report. "MIRACL" study of "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering"].
    Scheen AJ
    Rev Med Liege; 2000 Dec; 55(12):1064-6. PubMed ID: 11205194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial.
    Ahsan CH; Shah A; Ezekowitz M
    Curr Opin Cardiol; 2001 Nov; 16(6):390-3. PubMed ID: 11704711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Lange AP; Szucs TD
    Med Klin (Munich); 2004 Sep; 99(9):500-5. PubMed ID: 15372179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
    Olsson A; Casciano R; Stern L; Svangren P
    Int J Cardiol; 2004 Jul; 96(1):51-7. PubMed ID: 15203261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
    Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
    Olsson AG; Schwartz GG; Jonasson L; Linderfalk C
    Acta Physiol Scand; 2002 Oct; 176(2):147-50. PubMed ID: 12354174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
    Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A
    Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statins and unstable angina: MIRACL].
    Puel J
    Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 2):145-8. PubMed ID: 11240417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
    Correia LC; Spósito AC; Lima JC; Magalhães LP; Passos LC; Rocha MS; D'Oliveira A; Esteves JP
    Am J Cardiol; 2003 Aug; 92(3):298-301. PubMed ID: 12888137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of atorvastatin (80 mg) on recurrent ischemia in unstable angina pectoris or non-ST-elevation acute myocardial infarction.
    Correia LC; Magalhães LP; Santana O; Rocha MS; Passos LC; D'Oliveira A; Esteves JP; Spósito AC
    Am J Cardiol; 2003 Jun; 91(11):1355-7. PubMed ID: 12767434
    [No Abstract]   [Full Text] [Related]  

  • 18. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
    Pitt B; Waters D; Brown WV; van Boven AJ; Schwartz L; Title LM; Eisenberg D; Shurzinske L; McCormick LS
    N Engl J Med; 1999 Jul; 341(2):70-6. PubMed ID: 10395630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):85-6. PubMed ID: 15727720
    [No Abstract]   [Full Text] [Related]  

  • 20. What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
    Waters DD; Hsue PY
    Am J Cardiol; 2001 Oct; 88(7B):7J-16J. PubMed ID: 11595193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.